Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.

Display options

Format

Share it on

Full text links

Cancer Res. 1990 May 15;50(10):3043-7.

Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.

Cancer research

A Nakagawara, K Kadomatsu, S Sato, K Kohno, H Takano, K Akazawa, Y Nose, M Kuwano

Affiliations

Department of Pediatric Surgery, Faculty of Medicine, Kyushu University 60, Fukuoka, Japan.

PMID: 2185879
Free Article

Abstract

Genomic amplification of N-myc is an important prognostic indicator in neuroblastoma. The tumors with amplified N-myc are initially sensitive to chemotherapy but often acquire resistance to therapy, recur, and ultimately kill the patients. We measured amplification and expression of N-myc and expression of mdr-1 in 35 surgically resected neuroblastomas, before acquisition of drug resistance and in 4 recurrent tumors resistant to chemotherapy. The mdr-1 mRNA expression was found to be inversely correlated with the N-myc expression. The mdr-1 gene expression was at a low level in advanced stage and histologically undifferentiated neuroblastomas, the same group of tumors in which N-myc expression is elevated. A significantly better prognosis was noted in those patients whose tumors had a high level of mdr-1 expression and a low level of N-myc expression. The role, if any, of increased expression of mdr-1 in the acquisition of multidrug resistance in neuroblastoma remains unclear. However, the aggressive clinical behavior associated with N-myc amplification and/or expression appears to be linked to down-regulation of mdr-1 expression.

Similar articles

Applied Sciences: Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability.

Terpe HJ, Christiansen H, Berthold F, Gonzalez M, Altmannsberger M, Schulz A, Lampert F.
Cell Death Differ. 1994;1(2):123-8.
PMID: 17180025

Prognostic factors in purged marrow from patients with neuroblastoma receiving myeloablative treatment - tumor-cell number, N-myc protein, N-myc gene amplification and rate of hematologic recovery.

Gazitt Y, Cantor A, He Y, Koza S, Cohen R, Grahampole J.
Int J Oncol. 1993 Oct;3(4):755-61. doi: 10.3892/ijo.3.4.755.
PMID: 21573429

Therapy: modifying MYC expression.

Alderton GK.
Nat Rev Cancer. 2011 Aug 24;11(9):626-7. doi: 10.1038/nrc3132.
PMID: 21863048

Rare frequencey of point mutations for codon 12, 13 and 61 of ras gene in italian neuroblastoma.

Iolascon A, Badiali M, Pession A, Basso G, Losi L, Delgiudice E, Perrotta S, Cutillo S, Tonini G.
Int J Oncol. 1993 Sep;3(3):529-33. doi: 10.3892/ijo.3.3.529.
PMID: 21573396

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression.

Layer JP, Kronmüller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, Althoff K, Schramm A, Westermann F, Peifer M, Hartmann G, Tüting T, Kolanus W, Fischer M, Schulte J, Hölzel M.
Oncoimmunology. 2017 Apr 28;6(6):e1320626. doi: 10.1080/2162402X.2017.1320626. eCollection 2017.
PMID: 28680756

Transcriptional activity of N-myc and ngf-R in 50 primary human neuroblastomas as predictor for clinical outcome.

Christiansen N, Christiansen H, Berthold F, Lampert F.
Int J Oncol. 1993 Nov;3(5):853-7. doi: 10.3892/ijo.3.5.853.
PMID: 21573443

N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics.

Casinelli G, LaRosa J, Sharma M, Cherok E, Banerjee S, Branca M, Edmunds L, Wang Y, Sims-Lucas S, Churley L, Kelly S, Sun M, Stolz D, Graves JA.
Cell Death Discov. 2016 Dec 12;2:16082. doi: 10.1038/cddiscovery.2016.82. eCollection 2016.
PMID: 28028439

Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.

Affiliations

Abstract

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources